Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Website URL
Similar Companies1000
Dragonfly Therapeutics
Dragonfly Therapeutics develops cancer treatments using the immune system.
Sector
Subsector
Location
total rounds
Alyra Therapeutics
Alyra is a company that develops protein interaction inhibitors to treat cancer and rare diseases.
Sector
Subsector
Location
Abcuro
Abcuro develops immunomodulatory therapeutics for treating autoimmunity and cancer.
Sector
Subsector
Keywords
Location
total rounds
total raised
Olimmune
Olimmune is revolutionizing cancer treatment with its innovative oligonucleotide therapeutics that regulate the immune system.
Sector
Subsector
Keywords
Location
Financials
Funding Rounds3
Number of Funding Rounds
Money Raised
Their latest funding was raised on 21.07.2020. Their latest investor Astellas Venture Management. Their latest round Corporate Round
Gilead Sciences
Gilead Sciences is a biopharmaceutical company that develops and commercializes innovative medicines.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
Amgen Ventures
Amgen Ventures is a biotech-focused venture capital firm.
Sector
Subsector
Location
count Of Investments
count Of Exists
MPM Capital
MPM Capital invests in early-stage healthcare companies developing innovative oncology technologies.
Sector
Subsector
Location
count Of Investments
count Of Exists
Lightstone Ventures
Lightstone Ventures is a global venture capital fund that invests in biotech and medtech companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Abingworth
Abingworth collaborates with entrepreneurs to develop impactful health products in life sciences.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Astellas Venture Management
Astellas Venture Management is a California-based financial organization that targets investments in the biotechnology sector.
Sector
Subsector
Location
count Of Investments
count Of Exists
InterWest Partners
InterWest is a venture capital firm that invests in healthcare and IT companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Astellas Venture Management
Astellas Venture Management is a California-based financial organization that targets investments in the biotechnology sector.
Sector
Subsector
Location
count Of Investments
count Of Exists
InterWest Partners
InterWest is a venture capital firm that invests in healthcare and IT companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Co-Investors
Investors8
Number of lead investors
Number of investors
Astellas Venture Management
Astellas Venture Management is a California-based financial organization that targets investments in the biotechnology sector.
Sector
Subsector
Location
count Of Investments
count Of Exists
InterWest Partners
InterWest is a venture capital firm that invests in healthcare and IT companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Amgen Ventures
Amgen Ventures is a biotech-focused venture capital firm.
Sector
Subsector
Location
count Of Investments
count Of Exists
People
Founders5
Vijay Kuchroo
Vijay K. Kuchroo Co-Director of the Center for Infection and Immunity, Samuel L. Wasserstrom Professor, Department of Neurology, Associate Member, Broad Institute; Director, Evergrande Center for Immunologic Diseases, Harvard Medical School. Scientific Co-Founder and Advisory Board Member of Tizona Therapeutics. Dr. Kuchroo currently holds a title of Professor of Neurology at the Harvard Medical School and Associate Immunologist at the Brigham and Women’s Hospital, Boston. Dr. Kuchroo has published over 340 original papers and numerous review articles. Dr. Kuchroo’s major research interests are studying the autoimmune diseases, particularly the role of co-stimulation (Cell; 80: 707-18,1995), genetic basis of EAE and type 1 diabetes (Nature Genetics, 21: 158-161, 1999) and cell surface molecules and regulatory factors (Nature 2002. 415:536-41; Nature Immunol. 2003 4:1102-10. ) that contribute to susceptibility and resistance to autoimmune diseases. Dr. Kuchroo’s laboratory has made several transgenic mice that serve as animal models for human disease (Proceedings National Academy of Sciences USA, 97: 3412-3417, 2000; J Exp Med. 2003; 5;197:1073-81 ). Dr. Kuchroo is on the Editorial Boards of the journals: Journal of Experimental Medicine, International Immunology, Scandinavian Journal of Immunology, Cellular Immunology and an ad hoc reviewer for a number of Immunology related journals. He was a permanent member of the grants review board of the Juvenile Diabetes Research Foundation, New York and scientific review board of the National Multiple Sclerosis Society, New York. Dr. Kuchroo is also an ad hoc reviewer for the research grants for various study sections at the National Institutes of Health. Based on his contributions, Dr. Kuchroo was awarded the Javits Neuroscience Award by the National Institutes of Health in 2002 and Ranbaxy Prize, 2011. Dr. Kuchroo is the first incumbent of the Samuel L. Wasserstrom Chair in Neurology at Harvard Medical School. Dr. Kuchroo is an inventor on 25 patents and has been a founder of five different start-up biotech companies. Dr. Kuchroo is on the scientific advisory boards of Pfizer, Glaxo Smith Klein and Novartis. Dr. Vijay K. Kuchroo obtained a degree in Veterinary Medicine from the School of Veterinary Medicine, Hisar, India. He obtained a Ph.D. in Pathology from the department of veterinary pathology at the University of Queensland, Brisbane (Australia). Dr. Kuchroo received the Fred Z. Eager Research prize and medal for his Ph.D. research work at the University of Queensland. He served as Fogarty International Fellow at the National Institutes of Health, Bethesda for a year before joining the Department of Pathology, Harvard Medical School as a Research Fellow in the fall of 1986. Dr. Kuchroo joined the Center for Neurologic Diseases, Brigham and Women’s Hospital in 1992.
current job
organization founded
Vijay Kuchroo
Jedd Wolchok
Jdd Wolchok is the Associate Attending at Memorial Sloan Kettering Cancer Center.
current job
organization founded
Jedd Wolchok
Dario Vignali
Dario Vignali Vice Chair and Professor of Immunology, Department of Immunology, University of Pittsburgh School of Medicine; Co-Leader of the Cancer Immunology Program, University of Pittsburgh Cancer Institute (UPCI), Hillman Cancer Center. Scientific Co-Founder and Advisory Board Member of Tizona Therapeutics. Dr. Vignali’s labs focus on analysis of immune cell function in mouse model systems and disease models of cancer and autoimmune disease, and on inhibitory immune pathways in human cancers. Dr. Vignali’s research findings have been published in some of immunology’s leading journals, and he has been awarded five patents worldwide with several more awaiting approval. He also is a current member of the scientific advisory boards at two biopharmaceutical companies. Since 1993, Dr. Vignali worked at St. Jude Children’s Research Hospital in Memphis, Tennessee, and served as vice-chair of its immunology department since 2008. He taught in the Department of Pathology at the University of Tennessee Medical Center since 1996. He received his undergraduate education at North East London Polytechnic, now East London University, and completed his doctoral studies at the London School of Hygiene and Tropical Medicine at the University of London. Dr. Vignali completed two postdoctoral fellowships, one at the Institute for Immunology and Genetics at the German Cancer Research Center in Heidelberg, Germany, and the second in the Department of Biochemistry and Molecular Biology at Harvard University.
current job
organization founded
Dario Vignali
Drew Pardoll
Pardoll is an Abeloff Professor of Oncology, Medicine, Pathology and Molecular Biology and Genetics at the Johns Hopkins University, School of Medicine. He is Director of the Cancer Immunology in the Sidney Kimmel Comprehensive Cancer Center. Pardoll attended Johns Hopkins University, where he earned his M.D., Ph.D., in 1982 and completed his Medical Residency and Oncology Fellowship in 1985. He then worked for three years at the National Institutes of Health as a Medical Staff Fellow. Pardoll joined the departments of oncology and medicine at Johns Hopkins in 1988. Pardoll has published over 300 papers as well as over 20 book chapters on the subject of T cell immunology and cancer vaccines. He has served on the editorial board of the Journal of the National Cancer Institute and Cancer Cell, and has served as a member of scientific advisory boards for the Cancer Research Institute, the University of Pennsylvania Human Gene Therapy Gene Institute, Biologic Resources Branch of the National Cancer Institute, Harvard-Dana- Farber/Harvard Cancer Center, Cerus Corporation, Global Medical Products Corporation, Genencor International, Inc.Corporation, Cell Genesys, Inc. Corporation, Mojave Therapeutics, the American Association of Clinical Oncology and the American Association of Cancer Research. Pardoll has made a number of basic advances in Cellular Immunology, including the discovery of gamma - delta T cells, NKT cells and interferon-producing killer dendritic cells. Over the past two decades, Pardoll has studied molecular aspects of dendritic cell biology and immune regulation, particularly related to mechanisms by which cancer cells evade elimination by the immune system. He is an inventor of a number of immunotherapies, including GVAX cancer vaccines and Listeria monocytogenes based cancer vaccines. Pardoll’s basic immunology discoveries include the identification of ????-T cells, NKT cells and IKDC. He elucidated the role of Stat3 signaling in tumor immune evasion and in Th17 development, leading to the discovery that Stat3-driven Th17 responses promote carcinogenesis. Pardoll discovered one of the two ligands for the PD-1 inhibitory receptor and leads the Hopkins cancer immunology program that developed PD-1 pathway-targeted antibodies, demonstrating their clinical activity in multiple cancer types. His more than 300 articles cover cancer vaccines, gene therapies, cancer prevention technologies, recombinant immune modulatory agents for specific pathways that regulate immunity to cancer and infectious diseases. Pardoll attended Johns Hopkins University, where he earned his M.D., Ph.D., in 1982 and completed his Medical Residency and Oncology Fellowship in 1985. He then worked for three years at the National Institutes of Health as a Medical Staff Fellow. Pardoll joined the departments of oncology and medicine at Johns Hopkins in 1988.
current job
organization founded
Drew Pardoll
Employee Profiles11
Ina Cu
Executive assistant to chief executive officer
Shelly Pinto
Vice President of Finance and Controller